Skymab’s candidate ADCs rely on the combination of our GPCR knowledge with our linker payload technology platform.
THE LINKER – Skymab has developed a proprietary cleavable linker that has demonstrated:
- better anti-proliferative efficacy in vitro as compared to clinically validated linker platform
- better anti-tumor activity in vivo as compared to clinical validated ADCS in multiple animal models.
THE ADC CONSTRUCT – The ADC construct exhibits robust developability features and an enhanced therapeutic index with:
- Higher stability than clinical validated ADCs in human, rat and murine serum
- Better PK and higher DAR stability than clinical validated ADCs
- Higher in vivo efficacy than than clinical validated ADCs in multiple solid tumors as well as hematological malignancies